These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11046112)

  • 1. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.
    Friberg LE; Freijs A; Sandström M; Karlsson MO
    J Pharmacol Exp Ther; 2000 Nov; 295(2):734-40. PubMed ID: 11046112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats.
    Simonsen LE; Wählby U; Sandström M; Freijs A; Karlsson MO
    Anticancer Res; 2000; 20(3A):1519-25. PubMed ID: 10928065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose and time dependencies of 5-fluorouracil pharmacokinetics.
    Terret C; Erdociain E; Guimbaud R; Boisdron-Celle M; McLeod HL; Féty-Deporte R; Lafont T; Gamelin E; Bugat R; Canal P; Chatelut E
    Clin Pharmacol Ther; 2000 Sep; 68(3):270-9. PubMed ID: 11014408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Di Paolo A; Danesi R; Vannozzi F; Falcone A; Mini E; Cionini L; Ibrahim T; Amadori D; Del Tacca M
    Clin Pharmacol Ther; 2002 Dec; 72(6):627-37. PubMed ID: 12496744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats.
    Kobuchi S; Ito Y; Hayakawa T; Kuwano S; Baba A; Shinohara K; Nishimura A; Shibata N; Takada K
    Xenobiotica; 2014 Sep; 44(9):804-18. PubMed ID: 24650147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
    Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
    Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
    Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
    Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
    NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.
    Friberg LE; Hassan SB; Lindhagen E; Larsson R; Karlsson MO
    Eur J Pharm Sci; 2005 May; 25(1):163-73. PubMed ID: 15854812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
    Woo S; Krzyzanski W; Jusko WJ
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
    Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
    Xenobiotica; 2015 Jan; 45(1):19-28. PubMed ID: 25050790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibition.
    Keith B; Guo XD; Zentko S; Harold N; Schuler B; Quinn M; Shapiro J; Grem JL
    Clin Cancer Res; 2002 May; 8(5):1045-50. PubMed ID: 12006517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
    Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 5-fluorouracil and cyclophosphamide in depression rats.
    Duan JJ; Zhou T; Chen X; Wang Y; Wen YG; Xu F
    Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):427-36. PubMed ID: 22696869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J; Kraut EH; Balcerzak S; Grever M; D'Ambrosio S; Chan KK
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):445-53. PubMed ID: 12451470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.